ESR1 and breast carcinoma: Although our combination treatment can induce ERα re-activation in ER-negative breast cancer cells, it is still important to demonstrate the effective response of this combination by testing gene transcriptional change of ER-responsive downstream gene, progesterone receptor (PGR)33, in response to E2 or TAM stimulation.